BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 8, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

June 13, 2019

View Archived Issues

STAT6 siRNA sequences induce apoptosis and proliferation inhibition in colorectal/breast cancer

Read More

XMT-1536 well tolerated in phase I study in patients with solid tumors likely to express NaPi2b

Read More

First-in-human data presented for enapotamab vedotin in patients with advanced cancer

Read More

The BiTE immune-oncology therapeutic pasotuxizumab shows promising efficacy in mCRPC

Read More

Elderly cells found in regenerating organs

Read More

Kinase boost could be strategy for Lewy body busting

Read More

SCO-267, a novel GPR40 full agonist, improves glucose control in rats

Read More

Safety and efficacy of AB-BNCT in recurrent and locally advanced head and neck cancer

Read More

Phase I/IIa study of GEN-009 neoantigen vaccine containing autologous stimulatory peptides

Read More

Increased CCL14 expression linked to chronic kidney disease

Read More

Drug vulnerabilities due to tumor suppressor loss assayed

Read More

Alkermes initiates monotherapy expansion phase of ARTISTRY-1 study of ALKS-4230

Read More

ABBV-085 demonstrates manageable safety and preliminary activity in patients with sarcoma

Read More

Preliminary data presented from first-in-human study of AZD-5153

Read More

Genentech presents phase II data on fenebrutinib for rheumatoid arthritis with inadequate response

Read More

Daiichi Sankyo divulges GLP-1 receptor agonists

Read More

Roche patents gamma-secretase inhibitors

Read More

GemVax & KAEL presents new TGF-beta inhibitors and TNF production inhibitors

Read More

Pharvaris describes bradykinin B2 receptor antagonists

Read More

Dart NeuroScience synthesizes new PDE1B inhibitors

Read More

Topline data from phase III study of Molgradex in autoimmune alveolar pulmonary proteinosis

Read More

Phase IIa study of ALLOB used in lumbar spinal fusion procedure meets primary endpoints

Read More

Phase II study of Lyme disease vaccine candidate VLA-15 enters main study phase

Read More

IDMC recommends continuation of phase III study of masitinib in pancreatic cancer

Read More

IMV announces updated phase II findings for DPX-Survivac in DLBCL

Read More

Allele Biotechnology and Alpine BioTherapeutics enter research agreement on iPSCs for vision loss

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 5, 2025.
  • Mesothelin is biomarker, potential target in arthritic bone damage

    BioWorld Science
    In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
  • 3D rendering of prion structure

    Epigenetic technology could eliminate misfolded prion proteins

    BioWorld Science
    The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing